Hutchison China Meditech Limited Appointment of HSBC Bank plc as Broker in London (0968D)

TIDMHCM

RNS Number : 0968D

Hutchison China Meditech Limited

05 October 2018

Appointment of HSBC Bank plc as Joint Corporate Broker in London

London: Friday, October 5, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has appointed HSBC Bank plc as its joint Corporate Broker in London with immediate effect. Panmure Gordon (UK) Limited will continue to act as joint Corporate Broker in London and Nominated Advisor to Chi-Med in London in respect of the AIM rules.

About Chi--Med

Chi--Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi--Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi--med.com.

Forward--Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President, 
   Corporate Finance & Development                           [phone] 
  David Dible, Citigate Dewe Rogerson                        [phone] (Mobile) 
                                                              [e-mail] 
  Xuan Yang, Solebury Trout                                  [phone] (Mobile) 
                                                              [e-mail] 
 
Media Enquiries 
  UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson     [phone] (Mobile) 
                                                              [e-mail] 
  Americas - Brad Miles, Solebury Trout                      [phone] (Mobile) 
                                                              [e-mail] 
  Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick       [phone] (Mobile) 
                                                              [e-mail] 
  Mainland China - Sam Shen, Edelman                         [phone] (Mobile) 
                                                              [e-mail] 
 
Nominated Advisor 
  Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited   [phone] 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

APPEASESEDEPFEF

(END) Dow Jones Newswires

October 05, 2018 02:00 ET (06:00 GMT)